Head and Neck Squamous Cell Carcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 67 expanded access programs, clinical trials, and compassionate use pathways listed for Head and Neck Squamous Cell Carcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with head and neck squamous cell carcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 18 programs are currently active or recruiting, with the remaining 49 in other lifecycle stages. Sponsors actively running programs in this area include Merus N.V., H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), Providence Health & Services, Washington University School of Medicine, and others.
By recruiting status
Snapshot of where every Head and Neck Squamous Cell Carcinoma program currently sits in its lifecycle.
- Active / Recruiting18
- Inactive49
Top sponsors
Organisations running the most Head and Neck Squamous Cell Carcinoma programs in the directory.
- Merus N.V.4 programs
- H. Lee Moffitt Cancer Center and Research Institute3 programs
- National Cancer Institute (NCI)3 programs
- Providence Health & Services3 programs
- Washington University School of Medicine3 programs
- Alentis Therapeutics AG2 programs
- AstraZeneca2 programs
- M.D. Anderson Cancer Center2 programs
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2 programs
- University of California, San Diego2 programs
Head and Neck Squamous Cell Carcinoma programs (67)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on TER-2013 for Patients with Advanced Solid Tumors with Specific Genetic Changes — Terremoto Biosciences Inc.
- Study on IDP-001 for Advanced or Metastatic Solid Tumors — InduPro, Inc.
- Study on ALE.P02 as a Single Treatment for Adults with Certain CLDN1+ Solid Tumors — Alentis Therapeutics AG
- Study on the Safety of AZD6750 for Adults with Advanced or Metastatic Solid Tumors — AstraZeneca
- Study on Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) for Patients with Incurable Head and Neck Cancer — Washington University School of Medicine
- Study on Combining Pembrolizumab and Metformin for Patients with Advanced Head and Neck Cancer — Trisha Wise-Draper
- Study on Evorpacept (ALX148) with Pembrolizumab and Chemotherapy for Advanced Head and Neck Cancer — ALX Oncology Inc.
- Study on Palbociclib and Chemoradiation Therapy for HPV-Unrelated Head and Neck Cancer — Washington University School of Medicine
- Study on Immunotherapy and Radiation Before Surgery for Head and Neck Cancer — Providence Health & Services
- Study on NT219 Combined with Standard Biologic Therapy for Recurrent or Metastatic Head and Neck Cancer — University of Colorado, Denver
- Study on Paclitaxel, Carboplatin, and Cetuximab with Cetuximab, Docetaxel, Cisplatin, and Fluorouracil for Untreated Advanced Head and Neck Cancer — M.D. Anderson Cancer Center
- Phase II Study of Cetuximab and Cemiplimab Before Surgery for Head and Neck Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Study on New Treatment Combinations for Head and Neck Squamous Cell Carcinoma — Gilead Sciences
- Study on Volrustomig Alone or with Other Cancer Drugs for Advanced Solid Tumors — AstraZeneca
- Study on Adding BMX-001 or a Placebo to Usual Chemoradiation Therapy for Head and Neck Cancer — NRG Oncology
- Study on Cemiplimab and CDX-1140 Before Surgery for Stage III-IV Head and Neck Cancer — National Cancer Institute (NCI)
- Study on TT-10 and TT-4 as Single Agents and in Combination for Advanced Solid Tumors — Portage Biotech
- Study on VMD-928 Alone and with Pembrolizumab for Treating Solid Tumors or Lymphoma with High TrkA Levels — VM Oncology, LLC
- 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial — M.D. Anderson Cancer Center
- Phase 2a Study on Using Pegsitacianine for Detecting Cancer in Patients with Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) — University of Texas Southwestern Medical Center
- Phase 3 Study Comparing Petosemtamab with Other Treatments for Previously Treated Head and Neck Cancer — Merus N.V.
- Phase 3 Study Comparing Petosemtamab and Pembrolizumab with Pembrolizumab Alone for First-line Treatment of Head and Neck Cancer — Merus N.V.
- Study on VLS-1488 for Patients with Advanced Cancer — Volastra Therapeutics, Inc.
- Phase II Study of ACR-368 and Low Dose Gemcitabine for Recurrent or Metastatic Head and Neck Cancer — H. Lee Moffitt Cancer Center and Research Institute
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — Merus N.V.
- Study on Reducing Radiation and Chemotherapy in People with Head and Neck Cancer — Memorial Sloan Kettering Cancer Center
- Study on OR2805, a Monoclonal Antibody Targeting CD163, Alone and with Other Cancer Treatments — OncoResponse, Inc.
- Study on Pembrolizumab and Chemotherapy for Head and Neck Cancer — University of Chicago
- Study on IPN01194 for Adults with Advanced Solid Tumors — Ipsen
- Study on Cetuximab and Nivolumab for Recurrent or Metastatic Head and Neck Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Cetuximab After Immunotherapy for Treating Head and Neck Squamous Cell Cancer — Wake Forest University Health Sciences
- Comparing Chemotherapy and Immunotherapy with Radiation for Head and Neck Cancer — Loren Mell, MD
- Study on CUE-101 and Pembrolizumab for Advanced HPV-Related Head and Neck Cancer — Yale University
- FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma — Fulgent Pharma LLC.
- Study on GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo for Patients with Advanced Melanoma and Head and Neck Cancer — Providence Health & Services
- Study on GI-101 Alone or with Pembrolizumab, Lenvatinib, or Local Radiotherapy for Advanced Solid Tumors — GI Innovation, Inc.
- HPV-16 Vaccine and Pembrolizumab with Cisplatin for Intermediate Risk HPV-16-related Head and Neck Cancer — Dan Zandberg
- Study on IO102-IO103 and Pembrolizumab for First-line Treatment of Advanced Lung, Head and Neck, or Bladder Cancer — IO Biotech
- Study on Cemiplimab Before Surgery for Treating Resectable Lung, Liver, and Head and Neck Cancers in Adults — Regeneron Pharmaceuticals
- Study on Immunoradiotherapy Before Surgery for Head and Neck Cancer — Providence Health & Services
- Study on Pembrolizumab and IO102-103 Before Surgery for Head and Neck Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Pre-Surgery Treatment with Nivolumab and BMS-986253 for Head and Neck Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on PD-L1 t-haNK, N-803, and Cetuximab for Advanced Head and Neck Cancer — Glenn J. Hanna
- Study on Pembrolizumab and Cetuximab for Treating Recurrent or Metastatic Head and Neck Cancer — University of California, San Diego
- Study on MCLA-129 Antibody Treatment for Advanced Lung and Other Solid Tumors — Merus N.V.
- Phase 2 Study of Voyager V1 and Cemiplimab for Cancer Patients — Vyriad, Inc.
- Study on New Treatment for Advanced Solid Tumors Resistant to Standard Therapies — Klus Pharma Inc.
- Study on Pembrolizumab and Chemotherapy Before and After Surgery for Treatable, Returning Head and Neck Cancer — Dana-Farber Cancer Institute
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on Radiation Therapy With or Without Cisplatin for Patients With Stage III-IVA Head and Neck Cancer After Surgery — ECOG-ACRIN Cancer Research Group
- Study on Ramucirumab and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer — Washington University School of Medicine
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on Selective Additional Therapy for HPV-related Throat Cancer Based on Blood Test Results — University of Maryland, Baltimore
- Study on AHCC and Standard Treatment for HPV-Positive Head and Neck Cancer Patients — University of California, Irvine
- Study on Using Zr-Panitumumab to Detect Suspected Cancer Spread in Head and Neck Cancer — Andrei Iagaru
- Study on ALE.C04 for Patients with Head and Neck Cancer — Alentis Therapeutics AG
- Study on Pembrolizumab and Valemetostat for Treating Certain Head and Neck Cancers — National Cancer Institute (NCI)
- Study of NEO-201 in Solid Tumors Expansion Groups — Precision Biologics, Inc
- Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas — Immunitas Therapeutics
- Study on TU2218 and Pembrolizumab Combination for Advanced Solid Tumors — TiumBio Co., Ltd.
- Study of Zanzalintinib and Pembrolizumab vs Pembrolizumab Alone in Patients with PD-L1 Positive Recurrent or Metastatic Head and Neck Cancer — Exelixis
- Study on Tadalafil and Pembrolizumab for Recurrent or Metastatic Head and Neck Cancer — University of California, San Diego
- Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck — National Cancer Institute (NCI)
- Study on Tislelizumab with Other Investigational Drugs for Head and Neck Cancer — BeiGene
- Study on IL-2, Radiotherapy, and Pembrolizumab for Patients Not Responding to Checkpoint Blockade Therapy — Megan Daly, MD
- Study on Vaccination with Flt3L, Radiation, and Poly-ICLC for Cancer Treatment — Icahn School of Medicine at Mount Sinai
- Study on IPI-549 for Patients with Locally Advanced Head and Neck Cancer — Ezra Cohen
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Head and Neck Squamous Cell Carcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.